Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
- PMID: 11520775
- DOI: 10.1182/blood.v98.5.1302
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
Abstract
In an attempt to improve induction chemotherapy for older patients with acute myeloid leukemia (AML),1314 patients were randomized to 1 of 3 induction treatments for 2 courses of DAT (daunorubicin, cytarabine, and thioguanine) 3 + 10, ADE (daunorubicin, cytarabine, and etoposide) 10 + 3 + 5, or MAC (mitoxantrone-cytarabine). The remission rate in the DAT arm was significantly better than ADE (62% vs 50%; P =.002) or MAC (62% vs 55%; P =.04). This benefit was seen in patients younger and older than 70 years. There were no differences between the induction schedules with respect to overall survival at 5 years (12% vs 8% vs 10%). A total of 226 patients were randomized to receive granulocyte colony-stimulating factor (G-CSF) or placebo as supportive care from day 8 after the end of treatment course 1. The remission rate or survival were not improved by G-CSF, although the median number of days to recover neutrophils to 1.0 x 10(9)/L was reduced by 5 days. Patients who entered remission (n = 371) were randomized to stop after a third course (DAT 2 + 7) or after 6 courses, ie, a subsequent COAP (cyclophosphamide, vincristine, cytarabine, and prednisolone), DAT 2 + 5, and COAP. The relapse risk (81% vs 73%), disease-free survival (16% vs 23%), and overall survival at 5 years (23% vs 22%) did not differ between the 3-course or 6-course arms. In addition to a treatment duration randomization, 362 patients were randomized to receive 12-month maintenance treatment with low-dose interferon, but no benefit was seen with respect to relapse risk, disease-free survival, or overall survival.
Similar articles
-
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.Blood. 2001 Sep 1;98(5):1312-20. doi: 10.1182/blood.v98.5.1312. Blood. 2001. PMID: 11520776 Clinical Trial.
-
Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.Blood. 1997 Apr 1;89(7):2311-8. Blood. 1997. PMID: 9116274 Clinical Trial.
-
Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party.Br J Haematol. 1996 Jul;94(1):89-98. doi: 10.1046/j.1365-2141.1996.d01-1769.x. Br J Haematol. 1996. PMID: 8757514 Clinical Trial.
-
A systematic overview of chemotherapy effects in acute myeloid leukaemia.Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321. Acta Oncol. 2001. PMID: 11441935 Review.
-
[Current and new therapeutic strategies in acute myeloid leukemia].Gan To Kagaku Ryoho. 2005 Mar;32(3):292-6. Gan To Kagaku Ryoho. 2005. PMID: 15791811 Review. Japanese.
Cited by
-
Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies.Mar Drugs. 2024 Feb 28;22(3):114. doi: 10.3390/md22030114. Mar Drugs. 2024. PMID: 38535455 Free PMC article. Review.
-
Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia.Cancer Drug Resist. 2024 Feb 22;7:5. doi: 10.20517/cdr.2023.125. eCollection 2024. Cancer Drug Resist. 2024. PMID: 38434766 Free PMC article. Review.
-
Auto-hematopoietic stem cell transplantation or chemotherapy? Meta-analysis of clinical choice for AML.Ann Hematol. 2024 Jan 25. doi: 10.1007/s00277-024-05632-z. Online ahead of print. Ann Hematol. 2024. PMID: 38267560 Review.
-
LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway.Cancer Res Commun. 2023 Aug 18;3(8):1594-1606. doi: 10.1158/2767-9764.CRC-22-0478. eCollection 2023 Aug. Cancer Res Commun. 2023. PMID: 37599786 Free PMC article.
-
Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review.PLoS One. 2022 Dec 5;17(12):e0278578. doi: 10.1371/journal.pone.0278578. eCollection 2022. PLoS One. 2022. PMID: 36469519 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical